KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study
Swords, Ronan T., MD, PhD, FRCPI, FRCPath, Greenberg, Peter L., MD, Wei, Andrew H., MBBS, PhD, Durrant, Simon, MBBS, MRCS, LRCP, FRCP, FRCPath, Advani, Anjali S., MD, Hertzberg, Mark S., MBBS, PhD, FRACP, FRCPA, Lewis, Ian D., MBBS, PhD, Rivera, Gabriel, MD, Gratzinger, Dita, MD, PhD, Fan, Alice C., MD, Felsher, Dean W., MD, PhD, Cortes, Jorge E., MD, Watts, Justin M., MD, Yarranton, Geoff T., PhD, Walling, Jackie M., MB, ChB, PhD, Lancet, Jeffrey E., MD
Published in Leukemia research (01.11.2016)
Published in Leukemia research (01.11.2016)
Get full text
Journal Article
Corrigendum to “KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study” [Leuk. Res. 50 (Nov) (2016) 123–131. PubMed PMID: 27736729]
Swords, Ronan T., MD, PhD, Greenberg, Peter L., MD, Wei, Andrew H., MBBS, PhD, Durrant, Simon, MBBS, Advani, Anjali S., MD, Hertzberg, Mark S., MBBS, PhD, Lewis, Ian D., MBBS, PhD, Rivera, Gabriel, MD, Gratzinger, Dita, MD, PhD, Fan, Alice C., MD, Felsher, Dean W., MD, PhD, Cortes, Jorge E., MD, Watts, Justin M., MD, Yarranton, Geoff T., PhD, Walling, Jackie M., MB, ChB, PhD, Lancet, Jeffrey E., MD
Published in Leukemia research (01.08.2017)
Published in Leukemia research (01.08.2017)
Get full text
Journal Article